Jill Fredrickson

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 341 citations · Full text

Splenic Metabolic Activity Predicts Risk of Future Cardiovascular Events

Hamed Emami, Parmanand Singh, Megan H. MacNabb et al. · JACC. Cardiovascular imaging · 2015 · 249 citations · Full text

Obesity, Metabolic Syndrome, Cardiovascular Disease +8

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

David R. Spigel, Jamie E. Chaft, Scott Gettinger et al. · Journal of Thoracic Oncology · 2018 · 169 citations · Full text

Biomarker (Medicine), Therapeutic Drug Monitoring, Biomarker Analysis +7

Renal artery blood flow: quantitation with phase-contrast MR imaging with and without breath holding.

J. F. Debatin, R. Ting, H. Wegmüller et al. · Radiology · 1994 · 148 citations

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Saoirse Dolly, Andrew J. Wagner, Johanna C. Bendell et al. · Clinical Cancer Research · 2016 · 131 citations · Full text